Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 39 clinical trials
Blinatumomab in High-risk B-cell Precursor Acute Lymphoblastic Leukemia

The GRAALL-QUEST study is a Phase 2 study nested in the GRAALL-2014/B study (NCT02617004). The GRAALL-QUEST study evaluates the safety and the efficacy of blinatumomab-containing consolidation

kmt2a
cancer
residual disease
stem cell transplantation
remission
  • 0 views
  • 23 Jan, 2021
  • 1 location
Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphoblastic Leukemia (ALL)

This is a phase II interventional trial to evaluate the efficacy of blinatumomab followed by high-dose chemotherapy in the first-line treatment for Ph-negative acute lymphoblastic leukemia (ALL

  • 0 views
  • 25 Jan, 2021
  • 1 location
Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia

cells in the preparation. Polyclonal T cells can also be expanded in vitro in presence of Blinatumomab and recombinant human IL2 (rhIL2) and have been called BET (Blinatumomab-expanded T cells). They

  • 0 views
  • 26 Jan, 2021
  • 1 location
Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia

This study is designed to confirm the efficacy, safety, and tolerability of blinatumomab in patients with MRD of B- precursor ALL in complete hematological remission including patients with

remission
absolute neutrophil count
b-cell acute lymphoblastic leukemia
lymphoid leukemia
  • 8 views
  • 07 Mar, 2021
  • 41 locations
BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation

Blinatumomab (BLINCYTO) is a bi-specific T-cell engaging (BiTE) antibody construct that transiently links CD3-positive T cells to CD19-positive B-cells, inducing T-cell activation and subsequent

  • 2 views
  • 22 Jan, 2021
  • 42 locations
Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia

This phase II trial studies how well ibrutinib and blinatumomab work in treating patients with B acute lymphoblastic leukemia that has come back or is not responding to treatment. Ibrutinib may

lymphoma
monoclonal antibodies
cancer
philadelphia chromosome
monoclonal protein
  • 2 views
  • 25 Jan, 2021
  • 1 location
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

This phase I trial studies the side effects and best dose of lenalidomide and blinatumomab when given together in treating patients with non-Hodgkin lymphoma that has returned after a period of

lymphoma
lenalidomide
immunodeficiency
measurable disease
efavirenz
  • 107 views
  • 04 Apr, 2021
  • 15 locations
Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia

The present study aims at analyzing the response to treatment of adult patients homogeneously treated with supportive care, chemotherapy and blinatumomab.

cancer
blinatumomab
corticosteroids
lymphoid leukemia
  • 16 views
  • 24 Jan, 2021
  • 72 locations
D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia

This study aims at exploring the activity of a frontline approach based on dasatinib plus steroids administration as induction treatment, followed by the infusion of Blinatumomab, in adult Ph

dasatinib
blinatumomab
lymphoid leukemia
  • 108 views
  • 22 Jan, 2021
  • 27 locations
Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults.

Blinatumomab is a new active bispecific monoclonal antibody for treatment of lymphoid malignancies, including ALL (acute Lymphoblastic Leukemia ) whose activity for remission induction needs to

  • 12 views
  • 25 Jan, 2021
  • 16 locations